As well as providing mechanistic insights on how EML4–ALK V3 alters cellular properties, these data raise the prospect that Eg5 inhibitors may be valuable alternative treatments for patients with EML4–ALK V3–driven cancers. This evidence concerns the gene KIF11 and cancer.